{
    "clinical_study": {
        "@rank": "119401", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Eletriptan 40 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Eletriptan 80 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sumatriptan 25 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sumatriptan 50 mg", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study was to compare the efficacy, toleration and safety of eletriptan\n      40mg and 80mg, with sumatriptan 25mg and 50mg, and placebo when given orally to subjects\n      with an acute migraine."
        }, 
        "brief_title": "Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo", 
        "completion_date": {
            "#text": "January 1998", 
            "@type": "Actual"
        }, 
        "condition": "Migraine With or Without Aura", 
        "condition_browse": {
            "mesh_term": "Migraine Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who expected to suffer at least one acute attack of migraine, with or\n             without aura, each 6 weeks (The diagnosis of migraine was to comply with the criteria\n             proposed by the International Headache Society (IHS))\n\n          -  Subjects capable of taking medication as outpatients, and recording the effects of\n             such medication.\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast-feeding women\n\n          -  Migraine subjects who also suffered from concomitant frequent (non-migrainous)\n             headache, defined as more than six attacks per month on average."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1141", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01986270", 
            "org_study_id": "A160-104"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Matching Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Eletriptan 40 mg", 
                "description": "40mg oral", 
                "intervention_name": "Eletriptan 40 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Eletriptan 80 mg", 
                "description": "80mg oral", 
                "intervention_name": "Eletriptan 80 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sumatriptan 25 mg", 
                "description": "25mg oral", 
                "intervention_name": "Sumatriptan 25 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sumatriptan 50 mg", 
                "description": "50mg oral", 
                "intervention_name": "Sumatriptan 50 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Sumatriptan", 
                "Eletriptan"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 11, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A160-104&StudyName=Comparative%20Study%20of%20Oral%20Eletriptan%20%2840mg%20and%2080mg%29%2C%20Oral%20Sumatriptan%20%2825mg%20and%2050mg%29%20and%20Placebo"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Multicenter, Double-blind, Placebo Controlled, Parallel Group, Study of Two Dose Levels of Oral Eletriptan and Two Dose Levels of of Oral Sumatriptan Given for the Acute Treatment of Migraine", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 1998", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Headache response was defined as improvement from a severe or moderate headache at baseline to either a mild or absent headache post-dose.", 
            "measure": "Headache response at 1 hour after the first dose for the first attack.", 
            "safety_issue": "No", 
            "time_frame": "1 hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01986270"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "A pain free response was defined as an improvement from a severe or moderate headache at baseline to an absent headache post-dose.", 
            "measure": "Pain-free response at 1 hour after the first dose for the first attack.", 
            "safety_issue": "No", 
            "time_frame": "1 hour"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 1996", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}